Pfizer beats Q4 estimates, releases mid-stage GLP-1 trial results, and maintains guidance for full-year 2026
Pfizer slipped in premarket trading, down more than 4.5% as of 8:15 a.m. ET, after it reported earnings that beat Wall Street estimates, reaffirmed its full-year guidance, and released mid-stage trial results for its upcoming weight loss drug.
For the last three months of 2025, Pfizer reported:
Adjusted earnings per share of $0.66, compared to $0.57 analysts polled by FactSet were expecting.
Revenue of $17.6 billion, compared to $16.8 billion the Street was penciling in.
For the full-year 2026, Pfizer expects:
Annual adjusted earnings per share to hit between $2.80 to $3.00, compared to $2.97 analysts are currently expecting.
Annual revenues to hit between $59.5 to $62.5 billion, compared to $60.9 billion analysts are penciling in.
The company also released mid-stage trial results for its monthly weight loss shot, which it recently acquired through its purchase of Metsera. The results showed patients lost over 12.3% of their body weight at 28 weeks.
While the amount lost is in line with products already on the market, it is the first sign that less frequent dosing could still produce results. Late last year, Pfizer won a bidding war against Novo Nordisk, purchasing obesity biotech Metsera for $10 billion.
The pharmaceutical giant is working to reignite growth after demand for its COVID-19 products has waned and as some of its biggest moneymakers get nearer to the end of their patents’ lives.